Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8731963 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(a month ago) | |
US8731963
(Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(4 months from now) | |
US7668730 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(1 year, 4 months from now) | |
US7668730
(Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(1 year, 10 months from now) | |
US10864181 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(10 years from now) | |
US11253494 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(10 years from now) | |
US10213400 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(10 years from now) | |
US9486426 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(10 years from now) | |
US9050302 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(10 years from now) | |
US8772306 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(10 years from now) | |
US8772306
(Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(10 years from now) | |
US9486426
(Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(10 years from now) | |
US9050302
(Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(10 years from now) | |
US10864181
(Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(10 years from now) | |
US11253494
(Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(10 years from now) | |
US10213400
(Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 26, 2025 |
Pediatric Exclusivity (PED) | Apr 26, 2022 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of reducing adverse effects in patients who are concomitantly administered a salt of gamma-hydroxybutyrate and divalproex sodium; Method of treating patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered; Method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium
Dosage: SOLUTION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic